Reproductive Outcomes After Intracytoplasmic Sperm Injection (ICSI) With Surgically Retrieved Sperm.
SRS-ICSI outc
Reproductive Outcomes in Children Born Through Assisted Reproduction (ART): Focus on Intracytoplasmic Sperm Injection (ICSI) With Surgically Retrieved Sperm.
1 other identifier
observational
200,000
1 country
1
Brief Summary
This research project explores how the source of sperm affects outcomes in assisted reproductive technologies (ART), focusing on children conceived through intracytoplasmic sperm injection (ICSI) with surgically retrieved sperm (SRS). Outcomes will be compared to those from ICSI with ejaculated sperm and conventional IVF. Using national registry data from all IVF and ICSI treatments in Sweden between 2007 and 2023 (Q-IVF), the study applies artificial intelligence (AI) and machine learning (ML) to identify factors influencing success rates. The aim is to improve prediction models and support more personalized fertility treatments. Special emphasis is placed on understanding the potential risks and long-term health outcomes for children conceived using SRS, which may be associated with higher rates of genetic abnormalities. The results may help optimize care strategies for infertile couples.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2007
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedFirst Submitted
Initial submission to the registry
April 15, 2025
CompletedFirst Posted
Study publicly available on registry
April 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2027
ExpectedApril 30, 2025
April 1, 2025
17 years
April 15, 2025
April 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Biochemical pregnancy rate
Positive urinary pregnancy test after fresh or frozen embryo transfer per embryo transfer.
From enrollment to the end of treatment at 3 weeks
Clinical pregnancy rate
Presence of gestational sac at ultrasound control after fresh or frozen embryo transfer per embryo transfer.
From enrollment to the end of treatment at 8 weeks.
Live birth rate
Live birth per embryo transfer after fresh and frozen embryo transfer.
From enrollment to the end of treatment at delivery.
Secondary Outcomes (2)
Number of frozen embryos
From enrollment to the end of treatment at 5 days.
Miscarriage rate
From enrollment to the end of treatment before 22 weeks.
Study Arms (3)
IVF with ejaculated sperm
This group have gone through IVF with ejaculated sperm. Both fresh and frozen cycles are included.
ICSI with ejaculated sperm
This group have gone through ICSI with ejaculated sperm. Both fresh and frozen cycles are included.
ICSI with surgically retrieved sperm
This group have gone through ICSI with surgically retrieved sperm. Both fresh and frozen cycles are included.
Interventions
In vitro fertilization with or without ICSI with ejaculated and surgically retrieved sperm.
Eligibility Criteria
In this population-based project, data from the National Quality Registry Q-IVF will be employed to identify a birth cohort comprising all IVF treatments performed in Sweden between January 1, 2007, and December 31, 2023. This time frame aligns with the establishment in 2007 of the National Quality Registry for Assisted Reproduction (Q-IVF). This cohort will be followed until December 31, 2023, resulting in a 16-year period.
You may qualify if:
- All IVF treatments performed in Sweden during the study period.
- IVF treatments will be identified from the National register Q-IVF.
You may not qualify if:
- Children born from multiple pregnancies
- Children conceived through oocyte and sperm donation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Karolinska Institutetlead
- Göteborg Universitycollaborator
- Uppsala Universitycollaborator
Study Sites (1)
Department of Clinical Science, Intervention and Technology, Division of Obstetrics and Gynaecology, Karolinska Institute
Stockholm, 17177, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Panagiotis Tsiartas, Associate Professor
Karolinska Institutet
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
April 15, 2025
First Posted
April 30, 2025
Study Start
January 1, 2007
Primary Completion
December 31, 2023
Study Completion (Estimated)
May 30, 2027
Last Updated
April 30, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share
IPD will not be shared because the data will be retrieved from Q-IVF in anonymized form, ensuring that no individual can be identified. As such, there is no access to raw, identifiable data, and sharing is restricted to protect patient confidentiality and comply with data protection regulations.